Skip to main content
. Author manuscript; available in PMC: 2020 May 4.
Published in final edited form as: Nanomedicine. 2019 Jul 23;21:102067. doi: 10.1016/j.nano.2019.102067

Figure 7.

Figure 7.

SNARE maximum tolerated dose (MTD) and assessment of complement activation in pregnant dams. (A) Administration of SNAREs did not affect prenatal weight gain. Mice were weighted post-injection from GD 12 to GD 17, when mice were sacrificed for post-mortem analysis. (B) Average fetal weight (AFW), determined by dividing the total weight of the uteri by the number of non-resorbed fetuses, is shown. (C) Frequency of fetal resorption calculated as number of resorption/number of fetuses of treated compared to saline-treated mice. (D) C5a complement factor concentration in serum of mice treated with SNAREs showed no significant differences to the saline control. (E) C5b-9 complement factor concentration in serum of SNARE-treated mice also demonstrated no significant differences compared to saline control.